AC Immune S.A. (ACIU) Balance Sheet

The trajectory is unambiguous: each quarter's operating burn compounds into a larger accumulated deficit, and total assets have halved from $230.9M to $150.4M in under two years. Because the deterioration is funded by consuming the balance sheet rather than taking on debt, the company retains financial flexibility, but the shrinking equity base narrows the margin for error on milestone timing. Investors should monitor whether the 2026Q2 equity uptick from $31.5M to $35.2M marks a genuine inflection or merely a milestone-driven reprieve, given that the prior quarter marked the low point.

The sub-1.0 current ratio does not necessarily signal near-term distress because a large share of current liabilities appears to be deferred revenue rather than payables, but it does mean liquid assets no longer cover all short-term obligations on paper. With cash of $27.8M against historical FCF burn of roughly -$16M per loss quarter, the implied runway is only two to three quarters absent a milestone receipt or financing. This structure makes liquidity hostage to partnership event timing, a dependency the balance sheet itself cannot mitigate.

Goodwill's fixed absolute value masks its rising relative importance: as cash and other working-capital assets have been drawn down, the intangible block has become the single largest asset line. In a pre-commercial biotech whose value hinges on pipeline progression, an unchanged carrying value invites scrutiny, since a development setback could trigger impairment testing that writes the number down against a much thinner equity cushion. Meanwhile PPE has drifted down from $8.1M to $6.0M, consistent with the minimal-capex, outsourced model identified in the cash flow review.

There is no evidence of dilutive equity issuance masking the losses either, since equity moved in lockstep with the accumulated deficit trajectory, suggesting share count has been broadly stable. Stock-based compensation swings noted in the income statement review, from zero to $2.6M per quarter, may introduce modest future dilution, but it is immaterial against the scale of cash burn. The clean read is that equity quality is deteriorating purely through losses, which is the least ambiguous form of balance sheet decay but also the most fixable if milestone economics turn.